Tumor News and Research

RSS

FDA clears Nexstim’s new module for use with NBS System

Nexstim Oy, a medical device company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the NexSpeech module for use with the Navigated Brain Stimulation (NBS) System.

11 Jun 2012

Philips highlights portfolio of NM applications for IntelliSpace Portal at SNM 2012

At this year's SNM Annual Meeting, June 9-13, Royal Philips Electronics is highlighting its portfolio of nuclear medicine (NM) applications for IntelliSpace Portal, adding to its existing portfolio of CT, MR and multimodality applications.

11 Jun 2012

ADAM28 inhibits VWF-mediated cancer cell apoptosis and enhances lung metastases

ADAM28, a metalloproteinase belonging to the ADAM gene family, cleaves the von Willebrand factor (VWF) and inhibits VWF-mediated cancer cell apoptosis, thereby enhancing lung metastases, so inhibiting its expression gives a substantial reduction in lung metastases, according to a study published June 8 in the Journal of The National Cancer Institute.

11 Jun 2012

Vitamin D deficiency may account for unexplained disparities in cancer survival rates

A paper just published in Dermato-Endocrinology suggests that vitamin D deficiency may account for unexplained disparities in cancer survival rates between African and White Americans.

10 Jun 2012

New synthetic vaccine effective in killing HPV-derived cancer

Researchers at Moffitt Cancer Center have developed and tested in mice a synthetic vaccine and found it effective in killing human papillomavirus-derived cancer, a virus linked to cervical cancers among others.

10 Jun 2012

Steroids may slow progression of life-threatening skin reactions

Multi-national study results show that the progression of Steven Johnson Syndrome or Toxic Epidermal Necrolysis may be lengthened if corticosteroids are used prior to the onset of either condition.

8 Jun 2012

Prophylactic antibiotic regimens lack evidence of PARITY

Results from the PARITY study highlight the need for consensus in the prevention of infection in patients undergoing endoprosthetic limb reconstruction following sarcoma.

8 Jun 2012

Rheumatoid arthritis drug has added benefits

Treatment with anti-tumor necrosis factor drugs reduces the risk for cardiovascular events in patients with rheumatoid arthritis, researchers report.

8 Jun 2012

Discovery answers why mother's immune system does not reject developing fetus as foreign tissue

Researchers at NYU School of Medicine have made an important discovery that partially answers the long-standing question of why a mother's immune system does not reject a developing fetus as foreign tissue.

8 Jun 2012

Erivedge drug shows promise against advanced basal cell carcinoma

It's the most common form of skin cancer, but in its advanced stages, basal cell carcinoma has the potential to become disfiguring and life threatening. An international phase 2 study headed by Mayo Clinic led to the recent Food and Drug Administration approval of the first drug of its kind to help advanced basal cell carcinoma patients who have few treatment options.

8 Jun 2012

Tp53 genetic mutation may play an important role in prostate cancer

A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.

8 Jun 2012

Modulation Therapeutics receives MMRF grant for new multiple myeloma treatment

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $500,000 through its Biotech Investment Award (BIA) program to Modulation Therapeutics. Since the inception of this MMRF program in 2006, $11.5 million has been committed to 12 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

8 Jun 2012

NCI presents long-term outcomes from BiovaxID lymphoma vaccine Phase II trial at ASCO 2012

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the U.S. National Cancer Institute (NCI) presented long-term (median 10-year follow-up) outcomes at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012) from a Phase II BiovaxID lymphoma vaccine clinical trial.

8 Jun 2012

Scientists create cancer model built in the fruit fly Drosophila

Researchers from Mount Sinai School of Medicine developed a cancer model built in the fruit fly Drosophila, then used it to create a whole new approach to the discovery of cancer treatments. The result is an investigational compound AD80 that precisely targets multiple cancer genes.

8 Jun 2012

Adjuvant chemoradiotherapy boosts esophageal cancer survival

Chemoradiotherapy significantly improves the outcome of patients undergoing surgery for cancer of the esophagus or esophagogastric junction and is well tolerated, suggests research in The New England Journal of Medicine.

7 Jun 2012

Novartis, Foundation Medicine announce new agreement to offer genomic analysis

Foundation Medicine today announced a new agreement with Novartis to provide comprehensive genomic analysis in support of Novartis' clinical oncology programs.

7 Jun 2012

Clinical study demonstrates effectiveness of vismodegib in treating BCNS

A revolutionary clinical study has demonstrated the effectiveness of a new drug, vismodegib, in dramatically shrinking and preventing the formation of basal cell skin cancers - the most common cancer in the United States - in patients with basal cell nevus syndrome (BCNS), a rare genetic condition that causes hundreds to thousands of skin cancers primarily treated by surgical removal.

7 Jun 2012

New nanomedicine cancer treatments promise to reduce severity of side effects

A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the current edition of Chemical & Engineering News.

7 Jun 2012

Study reveals new information about origin of tumors

A study by Travis H. Stracker, researcher at the Institute for Research in Biomedicine (IRB Barcelona), in collaboration with scientists at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, reveals new information about the origin of tumors.

7 Jun 2012

AB Science announces data from development program of masitinib in GIST

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces today that data from the development program of masitinib in gastrointestinal stromal tumors (GIST) have been presented as part of three presentations delivered at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, 1-5 June in Chicago, Illinois.

6 Jun 2012